Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- SENTENCE label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater suggested that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety." provenance.
- SENTENCE label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater suggested that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety." provenance.
- SENTENCE label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater suggested that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety." provenance.
- SENTENCE label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater suggested that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety." provenance.
- SENTENCE label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater suggested that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety." provenance.
- SENTENCE label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater suggested that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety." provenance.
- SENTENCE label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater suggested that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety." provenance.
- SENTENCE label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater suggested that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety." provenance.
- SENTENCE label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater suggested that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety." provenance.
- SENTENCE label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater suggested that PGE2 and 5-iPF2α-VI can be a reliable biomarker of community oxidative anxiety." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd)." provenance.
- SENTENCE label "The RECOVERY trial deduced that dexamethasone reduced mortality by up to one-third among COVID-19 patients on mechanical ventilation and one-fifth among those who received supplemental oxygen." provenance.
- SENTENCE label "The RECOVERY trial deduced that dexamethasone reduced mortality by up to one-third among COVID-19 patients on mechanical ventilation and one-fifth among those who received supplemental oxygen." provenance.
- SENTENCE label "The RECOVERY trial deduced that dexamethasone reduced mortality by up to one-third among COVID-19 patients on mechanical ventilation and one-fifth among those who received supplemental oxygen." provenance.
- SENTENCE label "For people in their 60s, age specific months of mortality, abbreviated MOMa is 12 for Covid-19, 4 for cancer, 2.6 for coronary heart, and treatment of Covid-19 with dexamethasone reduces age specific months of mortality, abbreviated MOMa from 12 to 7 months." provenance.
- SENTENCE label "For people in their 60s, age specific months of mortality, abbreviated MOMa is 12 for Covid-19, 4 for cancer, 2.6 for coronary heart, and treatment of Covid-19 with dexamethasone reduces age specific months of mortality, abbreviated MOMa from 12 to 7 months." provenance.
- SENTENCE label "For people in their 60s, age specific months of mortality, abbreviated MOMa is 12 for Covid-19, 4 for cancer, 2.6 for coronary heart, and treatment of Covid-19 with dexamethasone reduces age specific months of mortality, abbreviated MOMa from 12 to 7 months." provenance.
- SENTENCE label "For people in their 60s, age specific months of mortality, abbreviated MOMa is 12 for Covid-19, 4 for cancer, 2.6 for coronary heart, and treatment of Covid-19 with dexamethasone reduces age specific months of mortality, abbreviated MOMa from 12 to 7 months." provenance.
- SENTENCE label "For people in their 60s, age specific months of mortality, abbreviated MOMa is 12 for Covid-19, 4 for cancer, 2.6 for coronary heart, and treatment of Covid-19 with dexamethasone reduces age specific months of mortality, abbreviated MOMa from 12 to 7 months." provenance.
- SENTENCE label "For people in their 60s, age specific months of mortality, abbreviated MOMa is 12 for Covid-19, 4 for cancer, 2.6 for coronary heart, and treatment of Covid-19 with dexamethasone reduces age specific months of mortality, abbreviated MOMa from 12 to 7 months." provenance.
- SENTENCE label "For people in their 60s, age specific months of mortality, abbreviated MOMa is 12 for Covid-19, 4 for cancer, 2.6 for coronary heart, and treatment of Covid-19 with dexamethasone reduces age specific months of mortality, abbreviated MOMa from 12 to 7 months." provenance.
- SENTENCE label "For people in their 60s, age specific months of mortality, abbreviated MOMa is 12 for Covid-19, 4 for cancer, 2.6 for coronary heart, and treatment of Covid-19 with dexamethasone reduces age specific months of mortality, abbreviated MOMa from 12 to 7 months." provenance.
- SENTENCE label "Importance: Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance: Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance: Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance: Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance: Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance: Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance: Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance: Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance: Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance: Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Importance Effective therapies for patients with coronavirus disease 2019 (COVID)-19) are needed, and clinical trial data have demonstrated that low-dose dexamethasone reduced mortality in hospitalized patients with COVID-19 who required respiratory support." provenance.
- SENTENCE label "Recent announcements indicated, without sharing any distinct published set of results, that the corticosteroid dexamethasone may reduce mortality of severe COVID-19 patients only." provenance.
- SENTENCE label "Recent announcements indicated, without sharing any distinct published set of results, that the corticosteroid dexamethasone may reduce mortality of severe COVID-19 patients only." provenance.
- SENTENCE label "Recent announcements indicated, without sharing any distinct published set of results, that the corticosteroid dexamethasone may reduce mortality of severe COVID-19 patients only." provenance.
- SENTENCE label "Recent announcements indicated, without sharing any distinct published set of results, that the corticosteroid dexamethasone may reduce mortality of severe COVID-19 patients only." provenance.
- SENTENCE label "Recent announcements indicated, without sharing any distinct published set of results, that the corticosteroid dexamethasone may reduce mortality of severe COVID-19 patients only." provenance.
- SENTENCE label "Recent announcements indicated, without sharing any distinct published set of results, that the corticosteroid dexamethasone may reduce mortality of severe COVID-19 patients only." provenance.
- SENTENCE label "Recent announcements indicated, without sharing any distinct published set of results, that the corticosteroid dexamethasone may reduce mortality of severe COVID-19 patients only." provenance.
- SENTENCE label "Recent announcements indicated, without sharing any distinct published set of results, that the corticosteroid dexamethasone may reduce mortality of severe COVID-19 patients only." provenance.
- SENTENCE label "Treatment with dexamethasone significantly reduced the number of cells expressing iNOS, but did not prevent primary demyelination." provenance.
- SENTENCE label "Treatment with dexamethasone significantly reduced the number of cells expressing iNOS, but did not prevent primary demyelination." provenance.
- SENTENCE label "Treatment with dexamethasone significantly reduced the number of cells expressing iNOS, but did not prevent primary demyelination." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "However, pre-treatment with dexamethasone (100 nM) caused significant reduction in the release of TNFα, IL-6, IL-1β and IL-8." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.
- SENTENCE label "(75 9% vs 40 0%, P-value=0 012) Further, early dexamethasone group showed a significantly shorter, total duration of oxygen supplementation, (10, 45 d, vs, 21, 61, d,, P-value=0, 003) and length of stay in the hospital (19 76 d, vs 27, 21, d,, P-value=0, 013), However,, extracorporeal membrane, oxygenation and in-hospital mortality rates were not significantly different between groups that received dexamethasone either within 24 hours of hypoxemia (early, dexamethasone, group) or 24 hours." provenance.